Prior observational studies suggest rivaroxaban is safe and effective among patients with
morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are …

Introduction Limited data exist on direct-acting oral anticoagulants in morbidly obese
patients with venous thromboembolism (VTE). We compared clinical and health/economic …

Background: Use of direct-acting oral anticoagulants (DOACs) in morbidly obese (BMI> 40
kg/m 2) patients for venous thromboembolism (VTE) treatment is not fully understood …

There is limited data evaluating clinical outcomes of rivaroxaban versus warfarin in obese
patients with venous thromboembolism (VTE). Our objective was to evaluate the …

Background Rivaroxaban is a first-line option for the management of venous
thromboembolism (VTE). However, limited data are available regarding its effectiveness in …

The pharmacokinetics of oral rivaroxaban are highly predictable and only affected to a
limited extent by bodyweight; therefore, dose adjustments for bodyweight are not required …

This study integrated 5 United States healthcare claims databases to evaluate the risk of
recurrent venous thromboembolism (VTE) and major bleeding (MB) among VTE patients …

Of the 1731 patients in the rivaroxaban arm of this study, 245 patients had a weight > 100
kg but further classification into weight > 120 kg or BMI > 40 kg/m SP 2 sp was not …

Introduction: Limited data exists on the safety and efficacy of direct‐acting oral
anticoagulants (DOAC) use in morbidly obese patients with venous thromboembolism …

Background: Limited clinical data exist describing the use of direct-acting oral
anticoagulants (DOACs) in patients with body mass index (BMI)> 40 kg/m2 or body weight> …